On the other hand, the measurement of serum cancer antigen 125 (CA125) and PRL levels are useful in monitoring adenomyosis and the effects of treatment12, 13, 14; therefore, changes in this hormone may be used to evaluate the efficacy of treatments. This evidence concerns the gene PRL and adenomyosis.